| http://www.w3.org/ns/prov#value | - alyst expectations.In the quarter ended Dec. 31, net income for the health-care company, which develops and manufactures products to treat conditions such as hemophilia, kidney disease and immune disorders, climbed to $463 million, or 82 cents per diluted share, up 9 percent from $423 million, or 72 cents per diluted share, in the year-ago period.Baxter???s net income in the final quarter of 2011
|
